Skip to main content
SpringerLink
Log in

Drugs, Fluids and Cancer

  • Chapter
  • First Online:
Textbook of Onco-Anesthesiology

  • 518 Accesses

Abstract

A greater understanding of the pathophysiology and pharmacology related to cancer has led to research into the possible role of the anesthesia drugs and techniques on cancer cell growth, host immunity, metastasis, and recurrence. The anesthetics may also exert a direct (non-immune) effect on the cellular biology of cancer cells by their interaction with specific cell signaling especially the hypoxic inducible factors. Surgery associated neuroendocrine, inflammatory, immune, and metabolic effects are amplified in cancer patients. Opioid remains an acceptable analgesic agent but has been reported to have some role in tumor recurrence. Propofol inhibits Matrix Metalloproteinases (MMP) and prevents tumor spread but has been shown to reduce Natural Killer (NK) cells whereas thiopentone might promote metastasis. Ketamine is associated with the reduction of both NK cell activity and its number. However, many of these reports are from animal models. Volatile agents appear to have negative effects concerning host immunity and tumor metastasis. Non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors may have benefits related to antiangiogenesis and tumor inhibition. Regional anesthesia has been studied with conflicting outcomes but benefits have been attributed to local anesthetic agents. Hypothermia influences function at the cellular level and negatively impacts adaptive immunity. Blood transfusion has an immunomodulatory effect and has an increased risk of cancer recurrence, and perioperative infections. The type and quantity of fluid based on an identified endpoint is also required for an optimal outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cata JP, Kurz A. Challenges in research related to perioperative cancer care and cancer outcomes. Best Pract Res Clin Anaesthesiol. 2013;27:457–64.

    Article  PubMed  Google Scholar 

  2. Colvin LA, Fallon MT, Buggy DJ. Cancer biology, analgesics, and anesthetics: is there a link? Br J Anaesth. 2012;109(2):140–3.

    Article  CAS  PubMed  Google Scholar 

  3. Huitink JM, Teoh WHL. Current cancer therapies—a guide for perioperative physicians. Best Pract Res Clin Anaesthesiol. 2013;27:481–92.

    Article  PubMed  Google Scholar 

  4. Gudaityte J, Dvylysand D, Simeliunaite I. Anaesthetic challenges in cancer patients: current therapies and pain management. Acta Med Litu. 2017;24:121–7.

    PubMed  PubMed Central  Google Scholar 

  5. Heaney A, Buggy DJ. Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth. 2012;109(S1):i17–28.

    Article  PubMed  Google Scholar 

  6. Goldfarb Y, Sorski L, Benish M, Levi B, Melamed R, Ben-Eliyahu S. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann Surg. 2011;253:798–810.

    Article  PubMed  Google Scholar 

  7. Yang W, Cai J, Zabkiewicz C, Zhang H, Ruge F, Jiang WG. Effects of anesthetics on recurrence and metastasis of cancer and clinical implications. World J Oncol. 2017;8(3):63–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sanders RD. Perioperative immunity: is there an anesthetic hangover? Br J Anaesth. 2014;112(2):210–2.

    Article  CAS  PubMed  Google Scholar 

  9. Kaye AD, Patel N, Bueno FR, Hymel B, Vadivelu N, Kodumudi G, et al. Effects of opiates, anesthetic techniques, and other perioperative factors on surgical cancer patients. Ochsner J. 2014;14:216–28.

    PubMed  PubMed Central  Google Scholar 

  10. Snyder GL, Greenberg S. Effect of anesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth. 2010;105(2):106–15.

    Article  CAS  PubMed  Google Scholar 

  11. Looney M, Doran P, Buggy DJ. Effect of anesthetic technique on serum vascular endothelial growth factor C and transforming growth factor beta in women undergoing anesthesia and surgery for breast cancer. Anesthesiology. 2010;113:1118–25.

    Article  CAS  PubMed  Google Scholar 

  12. Deegan CA, Murray D, Doran P, et al. Anesthetic technique and the cytokine and matrix metalloproteinase response to primary breast cancer surgery. Reg Anesth Pain Med. 2010;35:490–5.

    Article  PubMed  Google Scholar 

  13. Tavare AN, Perry NJS, Benzonana LL, Takata M, Ma D. Cancer recurrence after surgery: direct and indirect effects of anesthetic agents. Int J Cancer. 2012;130:1237–50.

    Article  CAS  PubMed  Google Scholar 

  14. Weimann J. Toxicity of nitrous oxide. Best Pract Res. 2003;17:47–61.

    CAS  Google Scholar 

  15. Melamed R, Bar-Yosef S, Shakhar G, Shakhar K, Ben-Eliyahu S. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesth Analg. 2003;97(5):1331–9.

    Article  CAS  PubMed  Google Scholar 

  16. Malsy M, Gebhardt K, Gruber M, Wiese C, Graf B, Bundscherer A. Effects of ketamine, s-ketamine, and MK 801 on proliferation, apoptosis, and necrosis in pancreatic cancer cells. BMC Anesthesiol. 2015;15:111.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Siddiqui RA, Zerouga M, Wu M, et al. Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells. Breast Cancer Res. 2005;7(5):R645–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Liu M, Zhang Y, Xiong JY, Wang Y, Lv S. Etomidate mitigates lipopolysaccharide-induced CD14 and TREM-1 expression, NF-kappaB activation, and pro-inflammatory cytokine production in rat macrophages. Inflammation. 2016;39(1):327–35.

    Article  CAS  PubMed  Google Scholar 

  19. Bruzzone A, Pinero CP, Castillo LF, Sarappa MG, Rojas P, Lanari C, Luthy IA. Alpha2-adrenoceptor action on cell proliferation and mammary tumour growth in mice. Br J Pharmacol. 2008;155(4):494–504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Jiao J, Wang Y, Sun X, Jiang X. Insights into the roles of midazolam in cancer therapy. Evid Based Complement Alternat Med. 2017;2017:Article ID 3826506, 9 pages. https://doi.org/10.1155/2017/3826506.

    Article  Google Scholar 

  21. Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased mu-opioid receptor expression in metastatic lung cancer. Br J Anaesth. 2014;113(Suppl1):i103–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Afsharimani B, Cabot P, Parat MO. Morphine and tumor growth and metastasis. Cancer Metastasis Rev. 2011;30(2):225–38.

    Article  CAS  PubMed  Google Scholar 

  23. Grandhi RK, Lee S, Abd-Elsayed A. Does opioid use cause angiogenes and metastasis? Pain Med. 2017;18(1):140–51.

    Article  PubMed  Google Scholar 

  24. Afsharimani B, Doornebal CW, Cabot PJ, Hollmann MW, Parat MO. Comparison and analysis of the animal models used to study the effect of morphine on tumour growth and metastasis. Br J Pharmacol. 2015;172(2):251–9.

    Article  CAS  PubMed  Google Scholar 

  25. Bajwa SS, Anand S, Kaur G. Anesthesia and cancer recurrences: the current knowledge and evidence. J Can Res Ther. 2015;11:528–34.

    Article  CAS  Google Scholar 

  26. Sacerdote P. Opioid-induced immunosuppression. Curr Opin Support Palliat Care. 2008;2(1):14–81.

    Article  PubMed  Google Scholar 

  27. Byrne K, Levins KJ, Buggy DJ. Can anesthetic-analgesic technique during primary cancer surgery affect recurrence or metastasis? Can J Anesth. 2016;63:184–92.

    Article  PubMed  Google Scholar 

  28. Harris RE. Cyclooxygenase-2 (COX-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology. 2009;17:55–67.

    Article  CAS  PubMed  Google Scholar 

  29. Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, Gupta K. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer. 2007;97:1523–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Gaspani L, Bianchi M, Limiroli E, Panerai AE, Sacerdote P. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J Neuroimmunol. 2002;129:18–24.

    Article  CAS  PubMed  Google Scholar 

  31. Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A, Ben-Eliyahu S. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol. 2008;15:2042–52.

    Article  PubMed  Google Scholar 

  32. Sakaguchi M, Kuroda Y, Hirose M. The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor. Anesth Analg. 2006;102:1103–7.

    Article  CAS  PubMed  Google Scholar 

  33. Lirk P, Hollmann MW, Fleischer M, Weber NC, Fiegl H. Lidocaine and ropivacaine, but not bupivacaine, demethylate deoxyribonucleic acid in breast cancer cells in vitro. Br J Anaesth. 2014;113(Suppl 1):i32–8.

    Article  CAS  PubMed  Google Scholar 

  34. Onkal R, Djamgoz MB. Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: clinical potential of neonatal Nav1.5 in breast cancer. Eur J Pharmacol. 2009;625:206–19.

    Article  CAS  PubMed  Google Scholar 

  35. Piegeler T, Votta-Velis EG, Liu G, Place AT, Schwartz DE, Beck-Schimmer B, Minshall RD, Borgeat A. Antimetastatic potential of amide-linked local anesthetics: inhibition of lung adenocarcinoma cell migration and inflammatory Src signalling independent of sodium channel blockade. Anesthesiology. 2012;117:548–59.

    Article  CAS  PubMed  Google Scholar 

  36. Cata JP, Ramirez MF, Velasquez JF, Di A, Popat KU, Gottumukkala V, et al. Lidocaine stimulates the function of natural killer cells in different experimental settings. Anticancer Res. 2017;37:4727–32.

    CAS  PubMed  Google Scholar 

  37. Wang HL, Yan HD, Liu YY, Sun BZ, Huang R, Wang XS, Lei WF. Intraoperative intravenous lidocaine exerts a protective effect on cell-mediated immunity in patients undergoing radical hysterectomy. Mol Med Rep. 2015;12(5):7039–44.

    Article  CAS  PubMed  Google Scholar 

  38. Jiang A, Zhao H, Cai J, Jiang WG. Possible effect of muscle-relaxant anaesthetics on invasion, adhesion and migration of breast cancer cells. Anticancer Res. 2016;36:1259–65.

    CAS  PubMed  Google Scholar 

  39. Jiang A, Zhao H, Liu X, Yu M, Chen J, Jiang WG. Possible effect of muscle-relaxant anaesthetics on invasion, adhesion and migration of breast cancer cells. Anticancer Res. 2017;37:4371–8.

    CAS  PubMed  Google Scholar 

  40. Ben-Eliyahu S, Shakhar G, Rosenne E, Levinson Y, Beilin B. Hypothermia in barbiturate-anesthetized rats suppresses natural killer cell activity and compromises resistance to tumor metastasis: a role for adrenergic mechanisms. Anesthesiology. 1999;91(3):732–40.

    Article  CAS  PubMed  Google Scholar 

  41. Beilin B, Shavit Y, Razumousky J, Wallach Y, Bessels H. Effects of mild perioperative hypothermia on cellular immune responses. Anesthesiology. 1998;89:1133–40.

    Article  CAS  PubMed  Google Scholar 

  42. Moslemi Kebria M, El-Nashar SA, Aletti GD, Cliby WA. Intraoperative hypothermia during cytoreductive surgery for ovarian cancer and perioperative morbidity. Obstet Gynecol. 2012;119:590–6.

    Article  PubMed  Google Scholar 

  43. Weber RS, Jabbour N, Martin RC. Anemia and transfusions in patients undergoing surgery for cancer. Ann Surg Oncol. 2008;15:34–45.

    Article  PubMed  Google Scholar 

  44. Churchhouse AM, Mathews TJ, Bride M, Dunning J. Does blood transfusion increase the chance of recurrence in patients undergoing surgery for lung cancer. Interact Cardiovasc Thorac Surg. 2012;14:85–90.

    Article  PubMed  Google Scholar 

  45. Chen G, Zhang FJ, Gong M, Yan M. Effect of perioperative autologous versus allogeneic blood transfusion on the immune system in gastric cancer patients. J Zhejiang Univ Sci B. 2007;8(8):560–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Ng T, Ryder BA, Chern H, Sellke FW, Machan JT, Harrington DT, Cioffi WG. Leukocyte-depleted blood transfusion is associated with decreased survival in resected early-stage lung cancer. J Thorac Cardiovasc Surg. 2012;143:815–9.

    Article  PubMed  Google Scholar 

  47. Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain. 2001;90(1–2):191–9.

    Article  CAS  PubMed  Google Scholar 

  48. Andersen BL, Farrar WB, Golden-Kreutz D, et al. Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst. 1998;90:30–6.

    Article  CAS  PubMed  Google Scholar 

  49. Colacchio TA, Yeager MP, Hildebrandt LW. Perioperative immunomodulation in cancer surgery. Am J Surg. 1994;167:174–9.

    Article  CAS  PubMed  Google Scholar 

  50. Bharati SJ, Chowdhury T, Bergese SD, Ghosh S. Anesthetics impact on cancer recurrence: what do we know? J Can Res Ther. 2016;12:464–8.

    Article  CAS  Google Scholar 

  51. González OP, Cuéllar-Guzmán LF, Soliz J, Cata JP. Impact of regional anesthesia on recurrence, metastasis, and immune response in breast cancer surgery. Reg Anesth Pain Med. 2017;42:1–6.

    Google Scholar 

  52. Kim R. Anesthetic technique and cancer recurrence in oncological surgery: unraveling the puzzle. Cancer Metastasis Rev. 2016;36:159. https://doi.org/10.1007/s10555-016-9647-8.

    Article  CAS  Google Scholar 

  53. Sekandarzad MW, van Zundert AAJ, Doornebal CW, Hollmann MW. Regional anesthesia and analgesia in cancer care: is it time to break the bad news. Curr Opin Anesthesiol. 2017;30:606–12.

    Article  Google Scholar 

  54. Wigmore TJ, Mohammed K, Jhanji S. Long-term survival for patients undergoing volatile versus IV anesthesia for cancer surgery: a retrospective analysis. Anesthesiology. 2016;124(1):69–79.

    Article  CAS  PubMed  Google Scholar 

  55. Enlund M, Berglund A, Andreasson K, Cicek C, Enlund A, Bergkvist L. The choice of anaesthetic—sevoflurane or propofol—and outcome from cancer surgery: a retrospective analysis. Upsala J Med Sci. 2014;119(3):251–61.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Lee JH, Kang SH, Kim Y, Kim HA, Kim BS. Effects of propofol-based total intravenous anesthesia on recurrence and overall survival in patients after modified radical mastectomy: a retrospective study. Korean J Anesthesiol. 2016;69(2):126–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Sahai SK. Perioperative assessment of the cancer patient. Best Pract Res Clin Anaesthesiol. 2013;27:465–80.

    Article  PubMed  Google Scholar 

  58. Chappell D, Jacob M. Role of the glycolcalyx in fluid management: small things matter. Best Pract Res Clin Anaesthesiol. 2014;28:227–34.

    Article  PubMed  Google Scholar 

  59. Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflugers Archiv. 2000;440(5):653–66.

    Article  CAS  PubMed  Google Scholar 

  60. Burbury K. Haemostatic challenges in the cancer patient: focus on the perioperative period. Best Pract Res Clin Anaesthesiol. 2013;27:493–511.

    Article  PubMed  Google Scholar 

  61. Jacob M, Chappell D. The third space—fact or fiction? Best Pract Res Clin Anaesthesiol. 2009;23:145–57.

    Article  PubMed  Google Scholar 

  62. Chappell D, Jacob M, Kiefer KH, Conzen P, Rehm M. Rational approach to perioperative fluid management. Anesthesiology. 2008;109:723–40.

    Article  PubMed  Google Scholar 

  63. Miller T. State of the art fluid management in the operating room. Best Pract Res Clin Anaesthesiol. 2014;28:261–73.

    Article  PubMed  Google Scholar 

  64. Lobo SM, Mendes CL, Rezende E, Dias FS. Optimising perioperative hemodynamics: what is new? Curr Opin Crit Care. 2013;19:346–52.

    Article  PubMed  Google Scholar 

  65. Veenestra G, Ince C, Boerma EC. Direct markers of organ perfusion to guide fluid therapy : when to start, when to stop. Best Pract Res Clin Anaesthesiol. 2014;28:261–73.

    Google Scholar 

  66. Manning MW, Dunkman WJ, Miller TE. Perioperative fluid and hemodynamic management within an enhanced recovery pathway. J Surg Oncol. 2017;116(5):592–600.

    Article  CAS  PubMed  Google Scholar 

  67. Makaryus R, Miller TE, Gan TJ. Current concepts of fluid management in enhanced recovery pathways. British Journal of Anesthesia. 2018;120(2):376–83.

    Article  CAS  Google Scholar 

  68. Thiele RH, Raghunathan K, Brudney CS, et al. American Society for Enhanced Recovery (ASER) and Perioperative Quality Initiative (POQI) joint consensus statement on perioperative fluid management within an enhanced recovery pathway for colorectal surgery. Perioper Med (Lond). 2016;5:24. https://doi.org/10.1186/s13741-016-0049-9.

    Article  Google Scholar 

  69. Cotton BA, Guy JS, Morris JA Jr, Abumrad NN. The cellular, metabolic, and systemic consequences of aggressive fluid resuscitation strategies. Shock. 2006;26:115–21.

    Article  CAS  PubMed  Google Scholar 

  70. Pinto ADS, Grigoletti SS, Marcadenti A. Fasting abbreviation among patients subjected to oncological surgery: systematic review. ABCD Arq Bras Cir Dig. 2015;28(1):70–3.

    Article  Google Scholar 

  71. Holubar SD, Hedrick T, Gupta R, et al. American Society for Enhanced Recovery (ASER) and Perioperative Quality Initiative (POQI) joint consensus statement on prevention of postoperative infection within an enhanced recovery pathway for elective colorectal surgery. Perioper Med (Lond). 2017;6:4. https://doi.org/10.1186/s13741-017-0059-2.

    Article  Google Scholar 

  72. Minto G, Miller TE. Monitoring needs and goal directed fluid therapy within an enhanced recovery programme. Anesthesiology Clin. 2015;33:35–49.

    Article  Google Scholar 

  73. Shida D, Tagawa K, Inada K, Nasu K, Seyama Y, Maeshiro T, et al. Modified enhanced recovery after surgery (ERAS) protocols for patients with obstructive colorectal cancer. BMC Surg. 2017;17:18.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Howells P, Bieker M, Yeung J. Oesophageal cancer and the anesthetist. BJA Educ. 2017;17(2):68–73.

    Article  Google Scholar 

  75. Jie HY, Ye JL, Zhou HH, Li YX. Perioperative restricted fluid therapy preserves immunological function in patients with colorectal cancer. World J Gastroenterol. 2014;20(42):15852–9.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Aditianingsih D, George YWH. Guiding priniciples of fluid and volume therapy. Best Pract Res Clin Anaesthesiol. 2014;28:249–60.

    Article  PubMed  Google Scholar 

  77. Lahtinen SL, Liisanantti JH, Poukkanen MM, Laurila PA. Goal-directed fluid management in free flap surgery for cancer of the head and neck. Minerva Anestesiol. 2017;83(1):59–68.

    Article  PubMed  Google Scholar 

  78. Eng OS, Arlow RL, Moore D, Chen C, Langenfeld JE, August DA, et al. Fluid administration and morbidity in transhiatal esophagectomy. Surg Res. 2016;200(1):91–7.

    Article  Google Scholar 

  79. Corcoran T, Emma Joy Rhodes J, Clarke S, Myles PS, Ho KM. Perioperative fluid management strategies in major surgery. Anesth Analg. 2012;114:640–51.

    Article  PubMed  Google Scholar 

  80. Wenkui Y, Ning L, Jianfeng G, Weiqin L, Shaoqiu T, Zhihui T, et al. Restricted peri-operative fluid administration adjusted by serum lactate level improved outcome after major elective surgery for gastrointestinal malignancy. Surgery. 2010;147(4):542–52.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anaesthesiology, Vijayanagar Institute of Medical Sciences (VIMS), Ballari, Karnataka, India

    S. Bala Bhaskar

  2. Department of Anesthesia and Critical Care, St John’s Medical College and Hospital, Bengaluru, Karnataka, India

    M. Manjuladevi

Authors
  1. S. Bala Bhaskar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Manjuladevi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Onco-Anaesthesia and Palliative Medicine, DR BRAIRCH, All India Institute of Medical Sciences, New Delhi, India

    Rakesh Garg

  2. Department of Onco-Anesthesiology and Palliative Medicine, Dr BRAIRCH and National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India

    Sushma Bhatnagar

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bala Bhaskar, S., Manjuladevi, M. (2021). Drugs, Fluids and Cancer. In: Garg, R., Bhatnagar, S. (eds) Textbook of Onco-Anesthesiology. Springer, Singapore. https://doi.org/10.1007/978-981-16-0006-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-0006-7_8

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-0005-0

  • Online ISBN: 978-981-16-0006-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation